Text Size

Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

This study has been terminated.
Sponsor:
Collaborator:
Sanofi-Synthelabo
Information provided by:
Swedish Medical Center
ClinicalTrials.gov Identifier:
NCT00316433
First received: April 18, 2006
Last updated: April 4, 2007
Last verified: April 2007
History of Changes
  Purpose

The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.


Condition Intervention Phase
Small Cell Lung Cancer
 Drug: Irinotecan (CPT-11)
Drug: Oxaliplatin (Eloxatin)
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by Swedish Medical Center:

Estimated Enrollment: 24
Study Start Date: February 2005
Study Completion Date: January 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Previously untreated extensive small cell lung cancer
  • No prior chemotherapy
  • No prior radiotherapy except for the treatment of brain metastases

Exclusion Criteria:

  • Prior treatment for extensive stage small cell lung cancer
  • Known hypersensitivity to any of the components of oxaliplatin or CPT-11
  • Greater than grade 2 peripheral neuropathy
  • Known HIV or Hepatitis B or C (active, previously treated or both)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00316433

Locations
United States, Washington
Swedish Medical Center Cancer Institute
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Swedish Medical Center
Sanofi-Synthelabo
Investigators
Principal Investigator: Howard (Jack) West, MD Swedish Medical Center Cancer Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00316433     History of Changes
Other Study ID Numbers: OX-03-099
Study First Received: April 18, 2006
Last Updated: April 4, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Oxaliplatin
 Irinotecan
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antineoplastic Agents, Phytogenic
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 18, 2013